Aerska, a biotechnology company developing RNA-based medicines for central nervous system diseases, has raised $39M in a Series A round to accelerate development of its proprietary brain shuttle platform.
Your go-to source for the latest Startup developments.
Would you like us to send you the latest news from the startup world?